Notice: This product is provided strictly for laboratory research use only
Getting it right means a smooth transition that preserves your progress and keeps your momentum going
For premenopausal women , discussion should cover: Contraceptive reliability and the need for additional precautions or alternative methods The possibility of improved fertility with weight loss, particularly in women with PCOS or obesity-related subfertility Monitoring for menstrual cycle changes, which may indicate improving metabolic health Pregnancy planning, as Mounjaro should be discontinued at least one month before conception according to the UK product information, and should be avoided during pregnancy and breastfeeding Risk of hypoglycaemia if also taking insulin or sulfonylureas, which may require dose adjustments of these medications For perimenopausal and postmenopausal women , considerations include: Potential reduction in peripheral oestrogen production with significant weight loss Monitoring for changes in menopausal symptoms Continued appropriateness of hormone replacement therapy (HRT) if already prescribed, noting that Mounjaro does not contraindicate HRT use Consider non-oral HRT routes if significant gastrointestinal symptoms occur Women with hormone-sensitive conditions such as oestrogen-receptor-positive breast cancer history, endometriosis, or uterine fibroids should discuss Mounjaro use with their oncologist or specialist
Adding value to beef portion steaks through measuring individual marbling
Neuroprotective Effects and the Brain-Gut Axis 2026 research has heavily focused on BPC-157s role in the Brain-Gut Axis, showing its ability to influence the central and peripheral nervous systems
Data are least squares mean (standard error) from mixed-model repeated measures for change in A ) pre-lunch appetite VAS scores, B ) Food Craving Inventory, C ) Food Craving Questionnaire-State, D ) Eating Inventory, and E ) Power of Food Scale, at week 3 in all randomized participants (placebo, n = 39
